Compare AIIR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIIR | NVAX |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2025 | 1996 |
| Metric | AIIR | NVAX |
|---|---|---|
| Price | $7.80 | $9.59 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 8.3K | ★ 4.9M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $5.29 | $6.20 |
| 52 Week High | $8.97 | $11.85 |
| Indicator | AIIR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 53.12 |
| Support Level | $6.63 | $9.14 |
| Resistance Level | $8.59 | $10.26 |
| Average True Range (ATR) | 0.89 | 0.63 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 47.33 | 42.78 |
AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.